Physician profile
Thomas Quigley
NPI 1578552220
$5,120.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $165 · 2021: $524 · 2022: $3,593 · 2023: $150 · 2024: $37.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $3,479.95 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $521.27 | 2019-2022 | |
| Alcon Vision LLC | $324.20 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $271.51 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $113.13 | 2022-2023 | Vyzulta, Miebo |
| New World Medical,INC. | $100.07 | 2019 | |
| Glaukos Corporation | $85.06 | 2019 | |
| Kala Pharmaceuticals, INC. | $43.90 | 2019-2022 | |
| Alcon Research LLC | $34.97 | 2019 | |
| Horizon Therapeutics Plc | $32.36 | 2023 | Tepezza |
| Heidelberg Engineering, INC. | $26.80 | 2023 | Spectralis |
| Catalyst Pharmaceuticals, INC. | $25.47 | 2022 | |
| Sun Pharmaceutical Industries INC. | $24.95 | 2021 | |
| Biotissue Holdings INC. | $19.49 | 2024 | |
| Amgen INC. | $17.62 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Quigley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.